Compare Stocks: IMVT vs. IBRX vs. SYRE vs. PRAX
Compare normalized stock price performance over 6 months, 1 year or 2 years. Each line starts at 0%, so different stock prices can be compared on the same scale.
IMVTIBRXSYREPRAX
Market Snapshot
Current market context for the selected companies.
IMVT
$43.93
Market Cap
$8.99B
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
IBRX
$8.24
Market Cap
$8.68B
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
SYRE
$93.72
Market Cap
$9.47B
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
PRAX
$377.11
Market Cap
$10.28B
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
Performance
Absolute returns and relative performance versus SPY.
| Metric | IMVT | IBRX | SYRE | PRAX |
|---|---|---|---|---|
| 1 Month | +12.9% | +18.2% | -6.2% | +27.5% |
| 1 Month vs SPY | +9.6% | +14.9% | -9.6% | +24.2% |
| 3 Months | +31.5% | +4.4% | +29.3% | +5.6% |
| 3 Months vs SPY | +29.5% | +2.4% | +27.3% | +3.6% |
| 6 Months | +61.3% | -13.6% | +113.6% | +8.5% |
| 6 Months vs SPY | +50.9% | -24.1% | +103.2% | -1.9% |
| 1 Year | +195.0% | +266.2% | +465.3% | +703.4% |
| 1 Year vs SPY | +175.9% | +247.1% | +446.1% | +684.2% |
| 2 Years | +35.3% | +87.3% | +252.7% | +605.7% |
| 2 Years vs SPY | -1.2% | +50.7% | +216.2% | +569.1% |
Growth & Profitability
Operating growth, margins and capital efficiency.
Valuation
Common valuation multiples shown side by side.
Cash Flow & Balance Sheet
Cash generation and leverage context.
Earnings Outlook
Upcoming earnings expectations when available.